Indero Marks 40th Study Live with Veeva RTSM
Veeva Systems (NYSE: VEEV) announced that Indero, formerly Innovaderm Research, has successfully completed its 40th study implementation using Veeva RTSM (Randomization and Trial Supply Management). This milestone demonstrates the successful standardization of Indero's clinical trial operations using Veeva's RTSM platform.
The specialized CRO has leveraged Veeva RTSM's advanced capabilities to enhance operational efficiency, improve process consistency, and streamline trial execution. Eric Hardy, senior director of biometrics at Indero, highlighted that the platform has enabled more efficient processes and better collaboration, ultimately accelerating the path to bringing therapies to market.
The partnership between Indero and Veeva has focused on developing and implementing standardized processes for long-term clinical trial success, with Veeva's enterprise standard RTSM approach contributing to greater efficiency and reliability in study execution.
Veeva Systems (NYSE: VEEV) ha annunciato che Indero, precedentemente Innovaderm Research, ha completato con successo la sua 40ª implementazione di studio utilizzando Veeva RTSM (Randomization and Trial Supply Management). Questo traguardo dimostra la standardizzazione riuscita delle operazioni di sperimentazione clinica di Indero attraverso la piattaforma RTSM di Veeva.
Il CRO specializzato ha sfruttato le avanzate capacità di Veeva RTSM per migliorare l'efficienza operativa, aumentare la coerenza dei processi e semplificare l'esecuzione degli studi. Eric Hardy, direttore senior della biometria di Indero, ha sottolineato che la piattaforma ha reso possibili processi più efficienti e una migliore collaborazione, accelerando così il percorso per portare le terapie sul mercato.
La partnership tra Indero e Veeva si è concentrata sullo sviluppo e l'implementazione di processi standardizzati per il successo a lungo termine delle sperimentazioni cliniche, con l'approccio standard RTSM di Veeva che contribuisce a una maggiore efficienza e affidabilità nell'esecuzione degli studi.
Veeva Systems (NYSE: VEEV) anunció que Indero, anteriormente Innovaderm Research, ha completado con éxito su 40ª implementación de estudio utilizando Veeva RTSM (Randomization and Trial Supply Management). Este hito demuestra la estandarización exitosa de las operaciones de ensayos clínicos de Indero utilizando la plataforma RTSM de Veeva.
El CRO especializado ha aprovechado las capacidades avanzadas de Veeva RTSM para mejorar la eficiencia operativa, aumentar la consistencia de los procesos y agilizar la ejecución de los ensayos. Eric Hardy, director senior de biometría en Indero, destacó que la plataforma ha permitido procesos más eficientes y una mejor colaboración, acelerando en última instancia el camino para llevar terapias al mercado.
La asociación entre Indero y Veeva se ha centrado en desarrollar e implementar procesos estandarizados para el éxito a largo plazo de los ensayos clínicos, con el enfoque estándar RTSM de Veeva contribuyendo a una mayor eficiencia y fiabilidad en la ejecución de los estudios.
Veeva Systems (NYSE: VEEV)는 Indero(이전의 Innovaderm Research)가 Veeva RTSM (Randomization and Trial Supply Management)를 사용하여 40번째 연구 구현을 성공적으로 완료했다고 발표했습니다. 이 이정표는 Veeva의 RTSM 플랫폼을 사용하여 Indero의 임상 시험 운영이 성공적으로 표준화되었음을 보여줍니다.
전문 CRO는 Veeva RTSM의 고급 기능을 활용하여 운영 효율성을 향상시키고, 프로세스 일관성을 개선하며, 시험 실행을 간소화했습니다. Indero의 생체 통계 수석 이사인 Eric Hardy는 이 플랫폼이 보다 효율적인 프로세스와 더 나은 협업을 가능하게 하여 궁극적으로 치료제를 시장에 내놓는 경로를 가속화했다고 강조했습니다.
Indero와 Veeva 간의 파트너십은 장기적인 임상 시험 성공을 위한 표준화된 프로세스 개발 및 구현에 중점을 두었으며, Veeva의 기업 표준 RTSM 접근 방식이 연구 실행의 효율성과 신뢰성을 높이는 데 기여하고 있습니다.
Veeva Systems (NYSE: VEEV) a annoncé qu'Indero, anciennement Innovaderm Research, a réussi à compléter sa 40ème mise en œuvre d'étude utilisant Veeva RTSM (Randomization and Trial Supply Management). Ce jalon démontre la standardisation réussie des opérations d'essais cliniques d'Indero grâce à la plateforme RTSM de Veeva.
Le CRO spécialisé a tiré parti des capacités avancées de Veeva RTSM pour améliorer l'efficacité opérationnelle, renforcer la cohérence des processus et rationaliser l'exécution des essais. Eric Hardy, directeur senior de la biométrie chez Indero, a souligné que la plateforme a permis des processus plus efficaces et une meilleure collaboration, accélérant ainsi le chemin vers la mise sur le marché des thérapies.
Le partenariat entre Indero et Veeva s'est concentré sur le développement et la mise en œuvre de processus standardisés pour le succès à long terme des essais cliniques, l'approche standard RTSM de Veeva contribuant à une plus grande efficacité et fiabilité dans l'exécution des études.
Veeva Systems (NYSE: VEEV) hat bekannt gegeben, dass Indero, ehemals Innovaderm Research, erfolgreich seine 40. Studienimplementierung mit Veeva RTSM (Randomization and Trial Supply Management) abgeschlossen hat. Dieser Meilenstein zeigt die erfolgreiche Standardisierung der klinischen Studienabläufe von Indero mithilfe der RTSM-Plattform von Veeva.
Die spezialisierte CRO hat die fortgeschrittenen Funktionen von Veeva RTSM genutzt, um die Betriebseffizienz zu steigern, die Prozesskonsistenz zu verbessern und die Durchführung von Studien zu optimieren. Eric Hardy, Senior Director für Biometrie bei Indero, hob hervor, dass die Plattform effizientere Prozesse und eine bessere Zusammenarbeit ermöglicht hat, was letztendlich den Weg zur Markteinführung von Therapien beschleunigt.
Die Partnerschaft zwischen Indero und Veeva konzentrierte sich auf die Entwicklung und Implementierung standardisierter Prozesse für den langfristigen Erfolg klinischer Studien, wobei der standardisierte RTSM-Ansatz von Veeva zu einer höheren Effizienz und Zuverlässigkeit bei der Durchführung von Studien beiträgt.
- Milestone achievement of 40 successful RTSM study implementations
- Enhanced operational efficiency and faster study timelines
- Successful standardization of clinical trial processes
- None.
Specialized CRO standardizes on Veeva RTSM to drive operational efficiency and faster study timelines
"As we continue to optimize our clinical trial operations, Veeva RTSM has driven more efficient processes and closer collaboration to ensure seamless execution," said Eric Hardy, senior director, biometrics at Indero. "Because of this added speed and effectiveness, we can help bring therapies to market faster, allowing our sponsors, sites, and patients to benefit sooner."
The launch of Indero's 40th RTSM study highlights the continued collaboration between the two organizations. Since first adopting Veeva RTSM, Indero has worked closely with Veeva to continuously refine and implement standardized processes that drive long-term success for its clinical trials.
"With its enterprise standard RTSM approach, Indero is achieving greater long-term efficiency and reliability in their studies," said Steve Simmerman, general manager, Veeva RTSM. "Partnering with Indero to standardize clinical processes will further accelerate study timelines, demonstrating a streamlined approach that can advance the industry."
Additional Information
To learn more about Veeva's enterprise standard RTSM, visit www.veeva.com/rtsm.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10- Q for the period ended October 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/indero-marks-40th-study-live-with-veeva-rtsm-302405321.html
SOURCE Veeva Systems
FAQ
How many RTSM studies has Indero completed using Veeva's platform?
What benefits has Indero gained from standardizing with Veeva RTSM?
How does Veeva RTSM (VEEV) impact clinical trial timelines?
What is the strategic importance of Indero's partnership with Veeva RTSM?
